Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.75 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.75 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.75 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.75 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.75 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.75 |
| ▸ | FAAH | O00519 | 4/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | CES2 | O00748 | 3/20 | 0.56 |
| ▸ | CES1 | P23141 | 3/20 | 0.56 |
| ▸ | PPARG | P37231 | 4/20 | 0.54 |
| ▸ | PPARD | Q03181 | 4/20 | 0.54 |
| ▸ | PPARA | Q07869 | 4/20 | 0.54 |
| ▸ | TSHR | P16473 | 3/20 | 0.54 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.54 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL572646 | 1.00 | HSP90AA1 (1.00) | HSP90AA1HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL2403692 | 1.00 | HSP90AA1 (1.00) | HSP90AA1HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL1290964 | 1.00 | HSP90AA1 (1.00) | HSP90AA1HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL331039 | 1.00 | HSP90AA1 (1.00) | HSP90AA1HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL4155670 | 1.00 | HSP90AA1 (1.00) | HSP90AA1HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL23203038 | 1.00 | HSP90AA1 (1.00) | HSP90AA1HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL5575814 | 1.00 | HSP90AA1 (1.00) | HSP90AA1HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL20915286 | 1.00 | HSP90AA1 (1.00) | HSP90AA1HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL20602650 | 1.00 | HSP90AA1 (1.00) | HSP90AA1HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL8977849 | 1.00 | HSP90AA1 (1.00) | HSP90AA1HDAC3HDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230247991-A1 | ANTIMICROBIAL MIXTURE CONTAINING 4-(3-ETHOXY-4-HYDROXYPHENYL)BUTAN-2-ONE AND AN ORGANIC ACID COMPOUND, AND COSMETIC COMPOSITION CONTAINING SAME | L'OREAL (FR) | 2023-08-10 | — | — | US | claimed |
| EP-3644733-B1 | ANTIMICROBIAL MIXTURE CONTAINING 4-(3-ETHOXY-4-HYDROXYPHENYL)BUTAN-2-ONE AND AN ORGANIC ACID COMPOUND, AND COSMETIC COMPOSITION CONTAINING SAME | OREAL (FR) | 2021-03-24 | — | — | EP | claimed |
| US-20210076676-A1 | ANTIMICROBIAL MIXTURE CONTAINING 4-(3-ETHOXY-4-HYDROXYPHENYL)BUTAN-2-ONE AND AN ORGANIC ACID COMPOUND, AND COSMETIC COMPOSITION CONTAINING SAME | L'OREAL (FR) | 2021-03-18 | — | — | US | claimed |
| EP-3661600-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF CONDITIONS RELATED TO METABOLIC SYNDROME | Epitracker, Inc. (US) | 2020-06-10 | — | — | EP | claimed |
| US-5174917-A | Compositions containing n-ethyl hydroxamic acid chelants | MONSANTO COMPANY (US) | 1992-12-29 | — | — | US | claimed |
| US-20260048037-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF COGNITIVE IMPAIRMENT, BEHAVIORAL CONDITIONS, AND CHRONIC PAIN | EPITRACKER INC (US) | 2026-02-19 | — | — | US | disclosed |
| US-12440473-B2 | Fatty acid analogs and their use in the treatment of cognitive impairment, behavioral conditions, and chronic pain | Epitracker, Inc. (US) | 2025-10-14 | — | — | US | disclosed |
| CN-118345256-A | Gallium extractant, preparation thereof and application thereof in gallium extraction | 深圳市中金岭南有色金属股份有限公司丹霞冶炼厂 | 2024-07-16 | — | — | CN | disclosed |
| US-11951088-B2 | Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome | Epitracker, Inc. (US) | 2024-04-09 | — | — | US | disclosed |
| US-20230247991-A1 | ANTIMICROBIAL MIXTURE CONTAINING 4-(3-ETHOXY-4-HYDROXYPHENYL)BUTAN-2-ONE AND AN ORGANIC ACID COMPOUND, AND COSMETIC COMPOSITION CONTAINING SAME | L'OREAL (FR) | 2023-08-10 | — | — | US | disclosed |
| CN-114058881-B | Regeneration method of gallium germanium hydroxamate extractant | 深圳市中金岭南有色金属股份有限公司丹霞冶炼厂 | 2023-06-23 | — | — | CN | disclosed |
| US-11653649-B2 | Antimicrobial composition including a dihydroxamic acid and methods of inhibiting microbial growth utilizing the same | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-20200345676-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF CONDITIONS RELATED TO METABOLIC SYNDROME | Epitracker, Inc. | 2020-11-05 | — | — | US | disclosed |
| US-10792266-B2 | Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome | Epitracker, Inc. (US) | 2020-10-06 | — | — | US | disclosed |
| EP-3644733-A1 | ANTIMICROBIAL MIXTURE CONTAINING 4-(3-ETHOXY-4-HYDROXYPHENYL)BUTAN-2-ONE AND AN ORGANIC ACID COMPOUND, AND COSMETIC COMPOSITION CONTAINING SAME | L'Oreal (FR) | 2020-05-06 | — | — | EP | disclosed |
| US-20200120929-A1 | ANTIMICROBIAL COMPOSITION INCLUDING A DIHYDROXAMIC ACID AND METHODS OF INHIBITING MICROBIAL GROWTH UTILIZING THE SAME | KIMBERLY CLARK CO (US) | 2020-04-23 | — | — | US | disclosed |
| US-20190117607-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF CONDITIONS RELATED TO METABOLIC SYNDROME | Epitracker, Inc. | 2019-04-25 | — | — | US | disclosed |
| WO-2019002391-A1 | ANTIMICROBIAL MIXTURE CONTAINING 4-(3-ETHOXY-4-HYDROXYPHENYL)BUTAN-2-ONE AND AN ORGANIC ACID COMPOUND, AND COSMETIC COMPOSITION CONTAINING SAME | L'OREAL (FR) | 2019-01-03 | — | — | WO | disclosed |
| WO-2019005064-A1 | ANTIMICROBIAL COMPOSITION INCLUDING A DIHYDROXAMIC ACID AND METHODS OF INHIBITING MICROBIAL GROWTH UTILIZING THE SAME | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2019-01-03 | — | — | WO | disclosed |
| WO-2009137462-A2 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | ENVIVO PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210076676-A1 | ANTIMICROBIAL MIXTURE CONTAINING 4-(3-ETHOXY-4-HYDROXYPHENYL)BUTAN-2-ONE AND AN ORGANIC ACID COMPOUND, AND COSMETIC COMPOSITION CONTAINING SAME | HAAO, CUTA, HAO2 | HSP90AA1 208/4885HDAC3 350/4885HDAC1 81/4885 |
| US-11653649-B2 | Antimicrobial composition including a dihydroxamic acid and methods of inhibiting microbial growth utilizing the same | DERA, DLD, DHODH | HSP90AA1 390/4885HDAC3 4491/4885HDAC1 3621/4885 |
| US-20190117607-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF CONDITIONS RELATED TO METABOLIC SYNDROME | FABP1, FASN, GPR119 | HSP90AA1 1840/4885HDAC3 1571/4885HDAC1 1076/4885 |
| US-20200120929-A1 | ANTIMICROBIAL COMPOSITION INCLUDING A DIHYDROXAMIC ACID AND METHODS OF INHIBITING MICROBIAL GROWTH UTILIZING THE SAME | DERA, DLD, DHODH | HSP90AA1 390/4885HDAC3 4491/4885HDAC1 3621/4885 |
| US-10792266-B2 | Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome | FABP1, FASN, GPR119 | HSP90AA1 1840/4885HDAC3 1571/4885HDAC1 1076/4885 |
| US-20230247991-A1 | ANTIMICROBIAL MIXTURE CONTAINING 4-(3-ETHOXY-4-HYDROXYPHENYL)BUTAN-2-ONE AND AN ORGANIC ACID COMPOUND, AND COSMETIC COMPOSITION CONTAINING SAME | HAAO, CUTA, HAO2 | HSP90AA1 235/4885HDAC3 351/4885HDAC1 82/4885 |
| US-11951088-B2 | Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome | FABP1, FASN, GPR119 | HSP90AA1 1840/4885HDAC3 1571/4885HDAC1 1076/4885 |
| US-20260048037-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF COGNITIVE IMPAIRMENT, BEHAVIORAL CONDITIONS, AND CHRONIC PAIN | CNR1, CNR2, FFAR1 | HSP90AA1 2641/4885HDAC3 258/4885HDAC1 1128/4885 |
| US-20200345676-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF CONDITIONS RELATED TO METABOLIC SYNDROME | FABP1, FASN, GPR119 | HSP90AA1 1840/4885HDAC3 1571/4885HDAC1 1076/4885 |
| US-12440473-B2 | Fatty acid analogs and their use in the treatment of cognitive impairment, behavioral conditions, and chronic pain | SCD, FABP7, ELOVL1 | HSP90AA1 2836/4885HDAC3 451/4885HDAC1 1594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.